Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06151223 · ClinicalTrials.gov registry record
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
A clinical trial of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT06151223: Recruiting study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Mayo Clinic.
NCT06151223 is a study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 5,000 participants, above the 375-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (1233% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06151223, a study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying early stages of pancreatic cancer, as well as people at high-risk.The study also aims to provide a platform for development of an interventional protocol for early detection of PDAC.
Primary Outcome
Sufficient biospecimens (blood and pancreatic juice) will be collected in 10 years from participants to provide a resource for nested case-control studies of promising biomarkers for discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC)..
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MRI
- OTHER Bio-specimen Collection: Blood
- OTHER Bio-specimen Collection: Pancreatic Juice
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2031-07-31 |
What NCT06151223 shows while recruiting
NCT06151223 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 375-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (1233% higher).
The record links to 4 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which MRI is the first listed.
NCT06151223 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06151223 about?
NCT06151223 is a clinical study titled "A Prospective Registry for Patients at High-Risk for Pancreatic Cancer". This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying e...
What is the current status of trial NCT06151223?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2021-07-13. Estimated completion is 2031-07-31.
What conditions does trial NCT06151223 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, PDAC.
What interventions are being tested in trial NCT06151223?
The interventions under investigation include: MRI (DIAGNOSTIC_TEST), Bio-specimen Collection: Blood (OTHER), Bio-specimen Collection: Pancreatic Juice (OTHER).
Who is sponsoring clinical trial NCT06151223?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06151223 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06151223's enrollment target sits among peer trials
5,000 5th of 278 higher than 272 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI